Should I buy or sell Glaukos stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks .

What is Glaukos' stock price target for 2024?

9 brokerages have issued 12 month price objectives for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $99.80 in the next year. This suggests a possible upside of 4.3% from the stock's current price. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts .

How have GKOS shares performed in 2024?

Glaukos' stock was trading at $79.49 on January 1st, 2024. Since then, GKOS shares have increased by 20.4% and is now trading at $95.71. View the best growth stocks for 2024 here .

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GKOS earnings forecast .

How can I listen to Glaukos' earnings call?

Glaukos will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) posted its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The medical instruments supplier had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative net margin of 42.79% and a negative trailing twelve-month return on equity of 22.67%. The company's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) earnings per share.

What ETFs hold Glaukos' stock?

ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) , Alger Weatherbie Enduring Growth ETF (AWEG) , SPDR S&P Health Care Equipment ETF (XHE) , Invesco S&P SmallCap Momentum ETF (XSMO) , Fidelity Disruptive Medicine ETF (FMED) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com . Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA) , Marvell Technology (MRVL) , PTC Therapeutics (PTCT) , PayPal (PYPL) , QUALCOMM (QCOM) , Alibaba Group (BABA) , Teladoc Health (TDOC) , Intel (INTC) , Advanced Micro Devices (AMD) and Boeing (BA) .

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SteelPeak Wealth LLC (0.01%). Insiders that own company stock include Alex R Thurman , Gilbert H Kliman , Joseph E Gilliam, Joseph E Gilliam , Marc Stapley , Mark J Foley and Thomas William Burns . View institutional ownership trends .

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)

Free GKOS Stock Alerts

$94.64

-2.25 (-2.32%)

(As of 02:45 PM ET)

Compare

Today's Range: $94.17
▼
$97.29
50-Day Range: $84.31
▼
$101.19
52-Week Range: $45.38
▼
$102.33

Volume: 151,493 shs
Average Volume: 671,251 shs
Market Capitalization: $4.68 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $99.80

Get Glaukos alerts:

Glaukos MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 4.3% Upside
$99.80 Price Target
Short Interest: Bearish
7.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.90
Upright™ Environmental Score
News Sentiment: 0.64
Based on 5 Articles This Week
Insider Trading: Selling Shares
$22.96 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.18) to ($1.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

271st out of 914 stocks

Surgical & Medical Instruments Industry

30th out of 94 stocks

2.4

Analyst's Opinion

Consensus Rating
Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Glaukos has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
7.05% of the outstanding shares of Glaukos have been sold short.
Short Interest Ratio / Days to Cover
Glaukos has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Glaukos has recently decreased by 4.64%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Glaukos does not currently pay a dividend.
Dividend Growth
Glaukos does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Glaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.
Environmental Sustainability
The Environmental Impact score for Glaukos is -0.90.

3.1

News and Social Media Coverage

News Sentiment
Glaukos has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Glaukos this week, compared to 4 articles on an average week.
Search Interest
3 people have searched for GKOS on MarketBeat in the last 30 days.
MarketBeat Follows
Only 3 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,959,418.00 in company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Glaukos is held by insiders.
Percentage Held by Institutions
99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Glaukos are expected to grow in the coming year, from ($2.18) to ($1.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Glaukos is -34.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Glaukos is -34.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Glaukos has a P/B Ratio of 10.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad GoldenCrest Metals

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

Learn More Now

About Glaukos Stock (NYSE:GKOS)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

GKOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GKOS Stock News Headlines

April 11, 2024 | insidertrades.com

Glaukos Co. (NYSE:GKOS) COO Sells $6,008,206.47 in Stock

April 10, 2024 | insidertrades.com

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 1,372 Shares

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

April 6, 2024 | insidertrades.com

Glaukos Co. (NYSE:GKOS) COO Sells $19,314.00 in Stock

April 4, 2024 | insidertrades.com

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 474 Shares

April 16, 2024 | businesswire.com

Glaukos Announces the Release of its 2023 Sustainability Report

April 13, 2024 | americanbankingnews.com

Glaukos (NYSE:GKOS) PT Raised to $100.00

April 13, 2024 | ca.news.yahoo.com

Speaker Johnson welcomes Japanese PM Kishida and his wife to the Capitol

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

April 12, 2024 | americanbankingnews.com

Joseph E. Gilliam Sells 59,801 Shares of Glaukos Co. (NYSE:GKOS) Stock

April 11, 2024 | finance.yahoo.com

Is Now The Time To Look At Buying Glaukos Corporation (NYSE:GKOS)?

April 11, 2024 | investing.com

Glaukos CFO sells over $163k in company stock

April 10, 2024 | finance.yahoo.com

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

April 10, 2024 | businesswire.com

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

April 9, 2024 | americanbankingnews.com

Glaukos (NYSE:GKOS) Rating Reiterated by Truist Financial

April 3, 2024 | msn.com

Glaukos gains on permanent J-code for iDose TR

April 3, 2024 | finance.yahoo.com

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

April 1, 2024 | finance.yahoo.com

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

March 25, 2024 | msn.com

Masimo considering JV for consumer division: WSJ

March 25, 2024 | msn.com

Activist Politan plans second proxy fight at Masimo (update)

March 22, 2024 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)

March 22, 2024 | markets.businessinsider.com

5 Analysts Have This To Say About Glaukos

March 22, 2024 | finance.yahoo.com

Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?

March 18, 2024 | finance.yahoo.com

GKOS Apr 2024 140.000 call

March 16, 2024 | finance.yahoo.com

GKOS Apr 2024 92.500 put

March 16, 2024 | ca.finance.yahoo.com

GKOS Apr 2024 80.000 put

February 27, 2024 | finance.yahoo.com

Glaukos Corp Director Mark Foley Sells 4,560 Shares

See More Headlines

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NYSE:GKOS
CUSIP: N/A
CIK: 1192448
Web: www.glaukos.com
Phone: (949) 367-9600
Fax: 949-367-9984
Employees: 907
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $99.80
High Stock Price Target: $120.00
Low Stock Price Target: $65.00
Potential Upside/Downside: +2.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-134,660,000.00
Net Margins: -42.79%
Pretax Margin: -42.49%
Return on Equity: -22.67%
Return on Assets: -11.50%

Debt

Debt-to-Equity Ratio: 0.77
Current Ratio: 5.34
Quick Ratio: 4.78

Sales & Book Value

Annual Sales: $314.71 million
Price / Sales: 15.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.46 per share
Price / Book: 10.27

Miscellaneous

Outstanding Shares: 49,470,000
Free Float: 45,611,000
Market Cap: $4.81 billion
Optionable: Optionable
Beta: 1.08

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Thomas William Burns (Age 63)
Chairman & CEO
Comp: $1.5M
Mr. Joseph E. Gilliam (Age 48)
President & COO
Comp: $974.59k
Mr. Alex R. Thurman (Age 54)
Senior VP & CFO
Comp: $373.4k
Mr. Chris M. Calcaterra (Age 64)
Executive Vice President of Global Commercial Operations
Comp: $198.66k
Dr. Tomas Navratil Ph.D. (Age 47)
Chief Development Officer
Comp: $721.51k
Dr. Mory Gharib Ph.D.
Co-Founder
Mr. Christopher William Lewis
Vice President of Investor Relations & Corporate Affairs
Ms. Diana A. Scherer
VP of Compliance & Deputy General Counsel
Ms. Michele M. Allegretto
Senior Vice President of Human Resources
Ms. Jane E. Rady (Age 76)
Senior Vice President of Corporate Strategy & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GKOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings or view top-rated stocks.
What is Glaukos' stock price target for 2024?: 9 brokerages have issued 12 month price objectives for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $99.80 in the next year. This suggests a possible upside of 4.3% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.
How have GKOS shares performed in 2024?: Glaukos' stock was trading at $79.49 on January 1st, 2024. Since then, GKOS shares have increased by 20.4% and is now trading at $95.71.
View the best growth stocks for 2024 here.
When is Glaukos' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GKOS earnings forecast.
How can I listen to Glaukos' earnings call?: Glaukos will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Glaukos' earnings last quarter?: Glaukos Co. (NYSE:GKOS) posted its quarterly earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The medical instruments supplier had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81 million. Glaukos had a negative net margin of 42.79% and a negative trailing twelve-month return on equity of 22.67%. The company's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) earnings per share.
What ETFs hold Glaukos' stock?: ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P SmallCap Momentum ETF (XSMO), Fidelity Disruptive Medicine ETF (FMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Corporate Culture Small Cap ETF (HAPS) and Principal Healthcare Innovators ETF (BTEC).

What guidance has Glaukos issued on next quarter's earnings?: Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.
What is Thomas W. Burns' approval rating as Glaukos' CEO?: 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Glaukos own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).
When did Glaukos IPO?: Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Who are Glaukos' major shareholders?: Glaukos' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SteelPeak Wealth LLC (0.01%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns.
View institutional ownership trends.
How do I buy shares of Glaukos?: Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GKOS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial